Evidence map›Paper›PMID 42089879›Full record

ArticleThe Journal of antimicrobial chemotherapy2026

Phenotypic and genotypic characterization of HMB-3, a metallo-beta-lactamase from Pseudomonas asiatica.

Jacqueline Findlay, John Michael Shaw, Patrice Nordmann, Philip Hinchliffe, Evelin Bucheli Laffer, Yannick Born, Helena M B Seth-Smith, Adrian Egli, Niels Pfennigwerth, James Spencer and 1 more

Abstract read
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jacqueline FindlayMedical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.ORCID 0000-0002-7335-9001
John Michael ShawSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.
Patrice NordmannMedical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.ORCID 0000-0002-1343-1622
Philip HinchliffeSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.
Evelin Bucheli LafferDepartment of Infectious Diseases and Hospital Hygiene, Kantonsspital Aarau AG, Aarau, Switzerland.
Yannick BornInstitute for Laboratory Medicine, Kantonsspital Aarau, Aarau, Switzerland.
Helena M B Seth-SmithInstitute of Medical Microbiology, University of Zurich, Zurich, Switzerland.
Adrian EgliInstitute of Medical Microbiology, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-3564-8603
Niels PfennigwerthGerman National Reference Centre for Multidrug-Resistant Gram-Negative Bacteria, Department of Medical Microbiology, Ruhr-University Bochum, Bochum, Germany.ORCID 0000-0002-6403-5646
James SpencerSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.
Laurent PoirelMedical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.ORCID 0000-0001-5160-5286

Funding

Federal Office of Public HealthSwiss National Science Foundation 10.001.529University of Zurich
6 · The paper itself

Abstract

objectivesWe describe the identification and characterization of the HMB-3 variant, produced by a P. asiatica isolate from a patient in Switzerland. MATERIALS AND

methodsA carbapenem-resistant P. asiatica isolate was sent to the Swiss National Reference Center for Emerging Antibiotic Resistance for investigation. Antibiotic susceptibility testing was performed according to CLSI guidelines. WGS was performed on Illumina and Oxford Nanopore platforms. The blaHMB alleles were cloned into the pCR-Blunt II-TOPO plasmid. Site-directed mutagenesis was performed on blaHMB-1 and blaHMB-3 inserted into the pTOPO plasmids. Purified HMB-1, HMB-3, NDM-1 and IMP-1 were used for steady state kinetic measurements of hydrolysis of selected beta-lactams. RESULTS AND DISCUSSION: The isolate was obtained from a tracheostomy wound swab. Susceptibility testing showed that it was resistant to all beta-lactams, except aztreonam; however, no classical carbapenemase genes were identified by routine testing. WGS produced a complete chromosome of 6.1 Mb but no plasmids, and identified a gene encoding a novel MBL, namely HMB-3, differing from HMB-1 by 23 amino acid substitutions. HMB-3 was chromosomally encoded and located within a 25.6 kb genomic island. HMB-3 conferred resistance to most beta-lactam antibiotics, except piperacillin (MIC 4 mg/L), aztreonam (0.125 mg/L) and cefiderocol (2 mg/L). Site-directed mutagenesis of blaHMB-1 and blaHMB-3 revealed that a single amino acid change, E181H/H181E, in active site loop 10, could significantly alter the MIC of cefiderocol. HMB-3 demonstrated increased hydrolytic activity against cefiderocol compared with HMB-1 and NDM-1.

conclusionsHere we described a novel MBL enzyme responsible for acquired resistance to carbapenems and reduced susceptibility to cefiderocol in Pseudomonas spp.

Indexed as

beta-LactamasesPseudomonasAnti-Bacterial Agentsbeta-LactamsCefiderocolGenotypeHumansMicrobial Sensitivity TestsMutagenesis, Site-DirectedPhenotypePseudomonas InfectionsSwitzerlandWhole Genome SequencingAnti-Bacterial Agentsbeta-Lactamasesbeta-LactamsCefiderocol

Identifiers

PMID42089879
PMCPMC13148013

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.